• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肺多形性癌对卡瑞利珠单抗（PD1单克隆抗体）单药治疗的部分缓解：一例报告

A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.

作者信息

Chen Yi, Zhang Hao, Shi Junfeng, Wang Tongshan

机构信息

Department of Oncology, Nanjing Pukou Central Hospital, Pukou Branch Hospital of Jiangsu Province Hospital, Nanjing 210000, People's Republic of China.

Department of Oncology, Jiangsu Provincial People's Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, People's Republic of China.

出版信息

Onco Targets Ther. 2020 Dec 3;13:12471-12476. doi: 10.2147/OTT.S279004. eCollection 2020.

DOI:10.2147/OTT.S279004
PMID:33299330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7721275/
Abstract

We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic carcinoma who showed partial response after a single treatment with camrelizumab (PD1 monoclonal antibody). The patient's tumor was positive for programmed cell death ligand 1 (PD-L1) and progressed rapidly after a course of chemotherapy. Fortunately, the tumors dramatically shrank after one cycle of camrelizumab, an anti-programmed cell death-1 (PD-1) antibody developed by Chinese Hengrui Medicine. In conclusion, camrelizumab may be a good treatment option, especially in tumors that express PD-L1.

摘要

我们报告了一例68岁男性患者，被诊断为肺多形性癌，在接受一次卡瑞利珠单抗（PD1单克隆抗体）治疗后出现部分缓解。该患者的肿瘤程序性细胞死亡配体1（PD-L1）呈阳性，在一个化疗疗程后病情迅速进展。幸运的是，在接受了一个周期的卡瑞利珠单抗（由中国恒瑞医药研发的一种抗程序性细胞死亡蛋白1（PD-1）抗体）治疗后，肿瘤显著缩小。总之，卡瑞利珠单抗可能是一种很好的治疗选择，尤其是对于表达PD-L1的肿瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/ba0061cc2101/OTT-13-12471-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/6f39ac77921f/OTT-13-12471-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/3624b09d6d89/OTT-13-12471-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/512ee9fe2ed1/OTT-13-12471-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/67a2653320f1/OTT-13-12471-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/6ee9a15678d2/OTT-13-12471-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/ba0061cc2101/OTT-13-12471-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/6f39ac77921f/OTT-13-12471-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/3624b09d6d89/OTT-13-12471-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/512ee9fe2ed1/OTT-13-12471-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/67a2653320f1/OTT-13-12471-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/6ee9a15678d2/OTT-13-12471-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c11/7721275/ba0061cc2101/OTT-13-12471-g0006.jpg

相似文献

1
A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.肺多形性癌对卡瑞利珠单抗（PD1单克隆抗体）单药治疗的部分缓解：一例报告
Onco Targets Ther. 2020 Dec 3;13:12471-12476. doi: 10.2147/OTT.S279004. eCollection 2020.
2
Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.安罗替尼改善了卡瑞利珠单抗诱导的反应性皮肤毛细血管内皮细胞增殖：一例报告
Transl Cancer Res. 2022 Aug;11(8):2940-2945. doi: 10.21037/tcr-22-426.
3
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
4
A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.卡瑞利珠单抗诱导鼻咽癌患者发生反应性皮肤毛细血管内皮细胞增生的病例报告及文献复习
Front Oncol. 2023 Nov 28;13:1280208. doi: 10.3389/fonc.2023.1280208. eCollection 2023.
5
Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.沙利度胺单药治疗实现程序性细胞死亡-1抑制剂卡瑞利珠单抗所致反应性皮肤毛细血管内皮细胞增殖完全缓解：一例报告
Exp Ther Med. 2023 May 16;26(1):324. doi: 10.3892/etm.2023.12023. eCollection 2023 Jul.
6
Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review.抗 PD-1 抗体卡瑞利珠单抗联合多柔比星在肺肉瘤样癌中显示出持久的缓解：病例报告和文献复习。
J Clin Pharm Ther. 2020 Dec;45(6):1489-1496. doi: 10.1111/jcpt.13234. Epub 2020 Aug 10.
7
Recall of reactive cutaneous capillary endothelial proliferation (RCCEP) induced by stereotactic body radiation therapy (SBRT) in a patient with lung squamous cell carcinoma.立体定向体部放射治疗（SBRT）诱发肺鳞状细胞癌患者出现反应性皮肤毛细血管内皮细胞增生（RCCEP）的病例回顾。
Exp Hematol Oncol. 2022 Oct 26;11(1):78. doi: 10.1186/s40164-022-00336-4.
8
Camrelizumab: an investigational agent for hepatocellular carcinoma.卡瑞利珠单抗：一种用于治疗肝细胞癌的在研药物。
Expert Opin Investig Drugs. 2022 Apr;31(4):337-346. doi: 10.1080/13543784.2022.2022121. Epub 2021 Dec 28.
9
An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.口腔中出现的类似牙龈瘤的卡瑞利珠单抗相关反应性皮肤毛细血管内皮增生（RCCEP）：一例报告。
Oral Oncol. 2023 May;140:106369. doi: 10.1016/j.oraloncology.2023.106369. Epub 2023 Mar 28.
10
Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.卡瑞利珠单抗相关免疫检查点抑制剂肺炎：病例报告及文献复习。
Ann Palliat Med. 2021 Jul;10(7):8460-8466. doi: 10.21037/apm-21-23. Epub 2021 May 12.

引用本文的文献

1
Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma.病例报告：1例肺多形性癌患者免疫治疗后长期缓解与生存
Front Immunol. 2024 Nov 15;15:1464900. doi: 10.3389/fimmu.2024.1464900. eCollection 2024.
2
Metastatic Pleomorphic Carcinoma of the Lung with Extensive Chromosomal Rearrangements: An Autopsy Case with a Literature Review.伴有广泛染色体重排的肺转移性多形性癌：一例尸检病例及文献复习
Intern Med. 2025 Feb 1;64(3):409-422. doi: 10.2169/internalmedicine.3478-24. Epub 2024 Jul 4.
3
Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.

本文引用的文献

1
Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.卡瑞利珠单抗联合吉西他滨、长春瑞滨和脂质体多柔比星治疗复发/难治性原发性纵隔 B 细胞淋巴瘤：一项单臂、开放标签、Ⅱ期临床试验。
Clin Cancer Res. 2020 Sep 1;26(17):4521-4530. doi: 10.1158/1078-0432.CCR-20-0514. Epub 2020 Jun 4.
2
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.卡瑞利珠单抗对比研究者选择的化疗作为晚期或转移性食管鳞癌（ESCORT）二线治疗：一项多中心、随机、开放标签、III 期研究。
Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13.
3
卡瑞利珠单抗引起的反应性皮肤毛细血管内皮细胞增生：16例病例报告
Indian J Dermatol. 2023 May-Jun;68(3):318-326. doi: 10.4103/ijd.ijd_343_22.
4
Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.安罗替尼改善了卡瑞利珠单抗诱导的反应性皮肤毛细血管内皮细胞增殖：一例报告
Transl Cancer Res. 2022 Aug;11(8):2940-2945. doi: 10.21037/tcr-22-426.
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.晚期肝细胞癌患者接受卡瑞利珠单抗治疗后出现反应性皮肤毛细血管内皮细胞增生：来自多中心 2 期试验的数据。
J Hematol Oncol. 2020 May 11;13(1):47. doi: 10.1186/s13045-020-00886-2.
4
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.卡瑞利珠单抗治疗既往接受过治疗的晚期肝细胞癌患者的多中心、开放标签、平行分组、随机、Ⅱ期临床试验。
Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.
5
Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer.卡瑞利珠单抗联合微波消融可提高晚期非小细胞肺癌的客观缓解率。
J Cancer Res Ther. 2019;15(7):1629-1634. doi: 10.4103/jcrt.JCRT_990_19.
6
Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.肺多形性癌的临床病理特征、手术结果、致癌状态及程序性死亡受体配体1（PD-L1）表达
Anticancer Res. 2019 Oct;39(10):5789-5795. doi: 10.21873/anticanres.13782.
7
Correction to: Camrelizumab: First Global Approval.对《卡瑞利珠单抗：首个全球获批》的更正
Drugs. 2019 Sep;79(13):1497. doi: 10.1007/s40265-019-01191-0.
8
Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.卡瑞利珠单抗（SHR-1210）与阿帕替尼联合治疗的一名患者早期肝细胞癌完全缓解
Dig Liver Dis. 2019 Oct;51(10):1488-1490. doi: 10.1016/j.dld.2019.07.005. Epub 2019 Aug 7.
9
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.抗 PD-1 单药治疗、单纯化疗及其联合治疗在晚期鼻咽癌中的比较安全性和疗效：来自标志性试验最新进展的研究结果。
J Immunother Cancer. 2019 Jun 25;7(1):159. doi: 10.1186/s40425-019-0636-7.
10
Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.局部放疗后纳武利尤单抗治疗肺多形性癌伴术后快速进展性复发的显著疗效。
Thorac Cancer. 2019 May;10(5):1263-1266. doi: 10.1111/1759-7714.13029. Epub 2019 Mar 12.